Returns diminishing, but kidney function kept improving a bit. The only hard data given concerns eGFR, though they say none of the patients died, and they were hospitalized less than patients in similar trials. Without the ability to compare population characteristics among trials, that doesn't mean much, of course.
News released after hours today, and I'm seeing no movement in the stock (not checking to to see if it's halted).
News 
Market Data 
Discover 
